Predictors of pre-procedural concentrations of direct oral anticoagulants: A prospective multicentre study

European Heart Journal

Volumn 38, Issue 31, 2017, Pages 2431-2439

  Godier, Anne ^a,b   Dincq, Anne Sophie ^c   Line Martin, Anne Ce ^b,d   Radu, Adrian ^e   Leblanc, Isabelle ^f   Antona, Marion ^g   Vasse, Marc ^e,h   Golmard, Jean Louis ⁱ   Mullier, Francois ^c   Gouin Thibault, Isabelle ^b,g,j  

^a FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^b Fondation Carpentier   (France)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d PERCY MILITARY HOSPITAL   (France)

^e FOCH HOSPITAL   (France)

^f INSTITUT MUTUALISTE MONTSOURIS   (France)

^g Institut Cochin   (France)

^h Dept Environ Med Natl Inst Publ HIth   (Norway)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Antiarrhythmic; Bleeding; Blood coagulation tests; Direct oral anticoagulant; Invasive procedure; Renal

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTITHROMBOCYTIC AGENT; APIXABAN; CREATININE; DABIGATRAN; DILTIAZEM; DRONEDARONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; QUINIDINE; RIVAROXABAN; VERAPAMIL;

ADULT; AGED; ARTICLE; BLOOD CLOTTING TEST; CREATININE CLEARANCE; DRUG WITHDRAWAL; FEMALE; HEMOSTASIS; HUMAN; INVASIVE PROCEDURE; MAJOR CLINICAL STUDY; MALE; MODERATE RENAL IMPAIRMENT; MULTICENTER STUDY; OBSERVATIONAL STUDY; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PREOPERATIVE CARE; TIME FACTOR; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION TESTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 85032727111     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehx403     Document Type: Article

References (30)

1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener H-C, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-2962.
2. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Heidbuchle H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M; RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: Results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012;126:343-348.
3. Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, Spyropoulos AC, Hankey GJ, Singer DE, Nessel CC, Mahaffey KW, Fox KAA, Califf RM, Becker RC; ROCKET AF Investigators. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: Results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 2014;129:1850-1859.
4. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener H-C, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P; Advisors. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. Eur Heart J 2016;ehw058.
5. Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD. Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. J Thromb Haemost 2016;14:875-885.
6. Sié P, Samama CM, Godier A, Rosencher N, Steib A, Llau JV, Van der Linden P, Pernod G, Lecompte T, Gouin-Thibault I, Albaladejo P. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis. Arch Cardiovasc Dis 2011;104:669-676.
7. Gallego P, Apostolakis S, Lip GYH. Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation. Circulation 2012;126: 1573-1576.
8. Godier A, Martin A-C, Leblanc I, Mazoyer E, Horellou M-H, Ibrahim F, Flaujac C, Golmard J-L, Rosencher N, Gouin-Thibault I. Peri-procedural management of dabigatran and rivaroxaban: Duration of anticoagulant discontinuation and drug concentrations. Thromb Res 2015;136:763-768.
9. Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI; Subcommittee on Control of Anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: Guidance from the SSC of the ISTH. J Thromb Haemost 2016;14:623-627.
10. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P; Working Group on Perioperative Haemostasis. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis 2013;106:382-393.
11. Steiner T, Böhm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, Laufs U, Nickenig G, Riess H, Röther J, Schellinger PD, Spannagl M, Veltkamp R. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 2013;102:399-412.
12. Seiffge DJ, Hooff R-J, Nolte CH, Béjot Y, Turc G, Ikenberg B, Berge E, Persike M, Dequatre-Ponchelle N, Strbian D, Pfeilschifter W, Zini A, Tveiten A, Næss H, Michel P, Sztajzel R, Luft A, Gensicke H, Traenka C, Hert L, Scheitz JF, De Marchis GM, Bonati LH, Peters N, Charidimou A, Werring DJ, Palm F, Reinhard M, Niesen W-D, Nagao T, Pezzini A, Caso V, Nederkoorn PJ, Kägi G, von Hessling A, Padjen V, Cordonnier C, Erdur H, Lyrer PA, Brouns R, Steiner T, Tatlisumak T, Engelter ST; NOACISP Study Group. Recanalization therapies in acute ischemic stroke patients: Impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome. Circulation 2015;132: 1261-1269.
13. Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, Al-Khatib SM, Dorian P, Ansell J, Commerford P, Flaker G, Lanas F, Vinereanu D, Xavier D, Hylek EM, Held C, Verheugt FWA, Granger CB, Lopes RD. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood 2014;124:3692-3698.
14. Summary of Product Characteristics; EMA. http://www.ema.europa.eu/docs/en- GB/document-library/EPAR---Product-Information/human/000829/WC500041 059.pdf (7 July 2017).
15. Faraoni D, Levy JH, Albaladejo P, Samama CM; Groupe d'intérêt en Hémostase Périopératoire. Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. Crit Care 2015;19:203.
16. Levy JH, Spyropoulos AC, Samama CM, Douketis J. Direct oral anticoagulants: new drugs and new concepts. JACC Cardiovasc Interv 2014;7:1333-1351.
17. Steinberg BA, Hellkamp AS, Lokhnygina Y, Halperin JL, Breithardt G, Passman R, Hankey GJ, Patel MR, Becker RC, Singer DE, Hacke W, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KAA, Califf RM, Piccini JP; ROCKET AF Steering Committee and Investigators. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. Heart Rhythm 2014;11:925-932.
18. Monreal M, Falga C, Valle R, Barba R, Bosco J, Beato JL, Maestre A; RIETE INVESTIGATORS. Venous thromboembolism in patients with renal insufficiency: Findings from the RIETE Registry. Am J Med 2006;119:1073-1079.
19. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH; American College of Chest Physicians. Prevention of VTE in nonsurgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141: E195S-e226S.
20. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW; American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e278S-e325S.
21. Lejus C, Desdoits A, Lambert C, Langlois C, Roquilly A, Gouin F, Asehnoune K. Preoperative moderate renal impairment is an independent risk factor of transfusion in elderly patients undergoing hip fracture surgery and receiving lowmolecular-weight heparin for thromboprophylaxis. J Clin Anesth 2012;24: 378-384.
22. Douketis JD, Wang G, Chan N, Eikelboom JW, Syed S, Barty R, Moffat KA, Spencer FA, Blostein M, Schulman S. Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure. J Thromb Haemost 2016;14:89-97.
23. Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou M-H, Laporte S, Siguret V, Lecompte T. Assessment of apixaban plasma levels by laboratory tests: Suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost 2014;111:240-248.
24. Schulman S, Carrier M, Lee AYY, Shivakumar S, Blostein M, Spencer FA, Solymoss S, Barty R, Wang G, Heddle N, Douketis JD. Periop dabigatran study group. perioperative management of dabigatran: A prospective cohort study. Circulation 2015;132:167-173.
25. Beyer-Westendorf J, Gelbricht V, Förster K, Ebertz F, Köhler C, Werth S, Kuhlisch E, Stange T, Thieme C, Daschkow K, Weiss N. Peri-interventional management of novel oral anticoagulants in daily care: Results from the prospective Dresden NOAC registry. Eur Heart J 2014;35:1888-1896.
26. Flaker GC, Theriot P, Binder LG, Dobesh PP, Cuker A, Doherty JU. Management of periprocedural anticoagulation: A survey of contemporary practice. J Am Coll Cardiol 2016;68:217-226.
27. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CAA, De Robertis E, Filipescu DC, Fries D, Görlinger K, Haas T, Imberger G, Jacob M, Lancé M, Llau J, Mallett S, Meier J, Rahe-Meyer N, Samama CM, Smith A, Solomon C, Van der Linden P, Wikkelsø AJ, Wouters P, Wyffels P. Management of severe perioperative bleeding. Eur J Anaesthesiol 2013;30:270-382.
28. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AGG, Hasselblad V, Ortel TL; BRIDGE Investigators. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015;373: 823-833.
29. Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M, Noack H, Oldgren J, Reilly P, Spyropoulos AC, Wallentin L, Connolly SJ. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Thromb Haemost 2015;113:625-632.
30. Lessire S, Douxfils J, Pochet L, Dincq AS, Larock AS, Gourdin M, Dogné JM, Chatelain B, Mullier F. Estimation of rivaroxaban plasma concentrations in the perioperative setting in patients with or without heparin bridging. Clin Appl Thromb Hemost 2016.